Form 4: Teva Pharmaceutical Executive VP Richard Daniell Executes Stock Sales and RSU Transactions

Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports the sale of ordinary shares and acquisition of restricted share units (RSUs) under a pre-arranged trading plan.

Summary

• Richard Daniell, Executive VP of European Commercial at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• On March 5, 2025, Daniell sold 22,576 ordinary shares at $15.9139 and 48,385 ordinary shares at $15.901.
• These sales were executed under a Rule 10b5-1 trading plan adopted on November 19, 2024.
• Daniell also acquired 22,576 ordinary shares through the vesting of restricted share units (RSUs) and was granted 69,182 additional RSUs.
• Following these transactions, Daniell directly owns 96,769 ordinary shares and 69,182 restricted share units.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, but the stock sales could be perceived negatively by some investors.

Positives

• The grant of 69,182 restricted share units to Richard Daniell indicates continued alignment of executive compensation with company performance.
• The vesting of 22,576 restricted share units shows that previous performance targets were met.

Negatives

• The sale of 70,961 ordinary shares by Richard Daniell could be interpreted negatively by investors, although it was executed under a pre-arranged trading plan.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create negative market sentiment.
• The weighted average sale prices indicate potential price volatility around the transaction date.

Future Outlook

The vesting schedule of the newly granted RSUs extends to March 5, 2029, suggesting a long-term incentive structure for the executive.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often part of compensation packages. Monitoring these transactions can provide insights into executive sentiment and company performance.

Comparison to Industry Standards

• Comparing Richard Daniell's compensation and stock ownership to those of executives at similar-sized pharmaceutical companies like Mylan (now Viatris) or Perrigo can provide a benchmark.
• Reviewing executive compensation disclosures in annual reports of companies like Novartis or Sanofi can offer insights into industry standards for RSU grants and vesting schedules.
• Analyzing Form 4 filings of executives at these comparable companies can reveal trends in stock sales and acquisitions.

Stakeholder Impact

• Shareholders may react to the stock sales, although the pre-arranged trading plan mitigates concerns about insider information.
• Employees may view the RSU grants as a positive sign of company commitment to executive compensation.

Key Dates